Synthetic Biologics reports second quarter 2012 financial results (PRNewswire) - Aug 14, 2012 - P2, N=164; Enrollment completed for RRMS trial; P2, N=64; Patient enrollment initiated for the study evaluating treatment of cognitive dysfunction in MS; Anticipated sales of $5B annually by 2017
Anticipated sales • Enrollment status • Multiple Sclerosis
|
|
Advancing Clinical Trial Programs
Completed enrollment of 164 patients in a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial evaluating the efficacy and safety of our proprietary oral formulation of estriol (Trimesta™) for the treatment of relapsing-remitting multiple sclerosis (MS) in women. According to various reports, sales of oral disease-modifying therapies for MS, of which Trimesta™, if and when approved, would be in a drug class, is expected to reach $5 billion annually by 2017.
Initiated patient enrollment in a second randomized, double-blind, placebo-controlled Phase II clinical trial of Trimesta™ for the treatment of cognitive dysfunction in MS. Charitable organizations have pledged to financially support a majority of this new MS clinical trial. As of August 1, 2012, 11 of 64 patients have been enrolled into this trial and patient recruitment continues...
(IR4)
|